N. Anthony Coles is Director at REGENERON PHARMACEUTICALS, INC. (REGN). They have made 18 open-market trades across 4 companies since 2009, most recently 2026-01-02.
CIK 0001197018
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 18 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CERE | SELL · 10b5-1 | 2024-07-01 | 2024-07-03 | $41.18 | $1.0M | +5.5% | N/A | N/A |
| CERE | SELL · 10b5-1 | 2024-06-03 | 2024-06-05 | $40.61 | $2.0M | +0.7% | -0.6% | N/A |
| CERE | SELL · 10b5-1 | 2024-05-10 | 2024-05-14 | $42.10 | $2.1M | -2.2% | -1.6% | N/A |
| CERE | SELL · 10b5-1 | 2024-04-01 | 2024-04-03 | $42.33 | $2.1M | -1.4% | +0.6% | -2.6% |
| CERE | SELL · 10b5-1 | 2024-03-04 | 2024-03-06 | $41.01 | $2.1M | +2.8% | +1.9% | -1.8% |
| CERE | SELL · 10b5-1 | 2024-02-29 | 2024-03-04 | $41.16 | $4.1M | +3.0% | +3.3% | -0.9% |
| CERE | SELL | 2024-02-07 | 2024-02-08 | $41.54 | $208K | -3.1% | -1.9% | -0.4% |
| CERE | SELL · 10b5-1 | 2024-01-02 | 2024-01-04 | $42.24 | $2.1M | +0.1% | -1.2% | +0.3% |
| CERE | SELL | 2023-11-14 | 2023-11-16 | $25.13 | $1.1M | +2.2% | +67.0% | +74.5% |
| CERE | SELL | 2023-11-07 | 2023-11-09 | $25.02 | $1.4M | +2.2% | +70.9% | +72.9% |
| CERE | SELL | 2023-11-02 | 2023-11-06 | $25.34 | $5.1M | +0.6% | +50.7% | +70.1% |
| CERE | SELL | 2023-09-07 | 2023-09-08 | $24.07 | $1.2M | -14.7% | -11.4% | +68.7% |
| CERE | SELL · 10b5-1 | 2023-07-11 | 2023-07-13 | $30.03 | $1.5M | +2.5% | -26.6% | -23.9% |
| CERE | SELL · 10b5-1 | 2023-06-01 | 2023-06-05 | $32.60 | $1.6M | +8.1% | -2.5% | -26.3% |
| CERE | SELL · 10b5-1 | 2023-05-04 | 2023-05-08 | $31.46 | $3.1M | -1.5% | +0.5% | -36.7% |
| CERE | SELL · 10b5-1 | 2023-04-11 | 2023-04-13 | $25.06 | $1.3M | +9.9% | +26.1% | +19.4% |
| CERE | SELL | 2023-03-02 | 2023-03-06 | $27.11 | $1.4M | -11.7% | -13.2% | +19.1% |
| CERE | SELL | 2023-02-07 | 2023-02-08 | $33.12 | $3.3M | -5.2% | -24.3% | +0.4% |
| CERE | SELL | 2023-01-05 | 2023-01-06 | $29.94 | $1.5M | +5.0% | +10.4% | -21.5% |
| REGN | SELL | 2022-12-28 | 2022-12-30 | $714.13 | $8.2M | -1.0% | +2.0% | +12.4% |
| CERE | SELL | 2022-12-09 | 2022-12-13 | $26.67 | $2.7M | +11.3% | +20.2% | -8.7% |
| REGN | SELL | 2022-09-06 | 2022-09-08 | $581.59 | $6.5M | -1.1% | +2.7% | +7.4% |
| REGN | SELL | 2021-09-15 | 2021-09-17 | $659.24 | $14.4M | -5.8% | -15.6% | -1.9% |
| REGN | SELL | 2021-08-17 | 2021-08-19 | $650.00 | $3.9M | +2.2% | -2.7% | -2.6% |
| REGN | SELL | 2021-08-13 | 2021-08-16 | $625.00 | $1.3M | +6.3% | +4.1% | +3.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| — |
| Total | $10.4M |